Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Novo Nordisk (CPSE:NOVO B) and United Bio-Technology reported positive phase 2 results for UBT251 in Chinese patients with type 2 diabetes.
UBT251 is a triple agonist targeting GLP-1, GIP and glucagon, designed as a next generation metabolic therapy.
A Novo Nordisk led global phase 1b/2a trial of UBT251 has started, with additional phase 2 and phase 3 studies planned globally and in China.
Novo Nordisk, known for its GLP-1 portfolio in diabetes and obesity care, is extending its reach with triple agonist candidates such as UBT251. For investors tracking CPSE:NOVO B, this adds another late stage asset in metabolic disease alongside existing treatments that focus on single hormone pathways.
The progress of UBT251 provides an additional data point to monitor as multi agonist therapies receive more attention in obesity and diabetes drug development. As the global phase 1b/2a study advances and larger trials begin, the scale, design and readouts of those studies will be central to understanding how important this program may become within Novo Nordisk’s broader pipeline.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at Apr 2026
✅ Price vs Analyst Target: At DKK236.9, the share price sits about 24% below the DKK309.8 analyst price target.
✅ Simply Wall St Valuation: Shares are flagged as trading around 67.9% below the platform’s estimated fair value.
❌ Recent Momentum: The 30 day return is roughly flat at -0.06%, which is slightly negative despite the trial update.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.
📊 Positive phase 2 data for UBT251 and progression into global trials add another late stage metabolic candidate alongside the existing GLP 1 franchise.
📊 Watch how UBT251 trial size, endpoints and timing evolve, and how this lines up with earnings, a P/E of 10.3 and the current discount to the DKK309.8 price target.
⚠️ Simply Wall St highlights 5 risks, including high debt and share price volatility, which remain relevant as development costs and news flow increase.
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can visit the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com